Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.

UNLABELLED We previously described a highly flexible bispecific antibody (bs-mAb) pretargeting procedure using a multivalent, recombinant anti-CEA (carcinoembryonic antigen) x anti-HSG (histamine-succinyl-glycine) fusion protein with peptides radiolabeled with 111In, 90Y, 177Lu, and 99mTc. The objective of this study was to develop a radioiodination procedure primarily to assess PET imaging with 124I. METHODS A new peptide, DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2 (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid), was synthesized and conditions were established for radioiodination with yields of approximately 70% for 131I and 60% for 124I. Pretargeting with the 131I- and 124I-labeled peptide was tested in nude mice bearing LS174T human colonic tumors that were first given the anti-CEA x anti-HSG bs-mAb. Imaging (including small-animal PET) and necropsy data were collected at several intervals over 24 h. Comparisons were made between animals given 124I-anti-CEA Fab', 18F-FDG, the same peptide radiolabeled with 111In and pretargeted with the bs-mAb, and the radioiodinated peptide alone. RESULTS The radioiodinated peptide alone cleared quickly from the blood with no evidence of tumor targeting, but when pretargeted with the bs-mAb, tumor uptake increased 70-fold, with efficient and rapid clearance from normal tissues, allowing clear visualization of tumor within 1-2 h. Tumor uptake measured at necropsy was 3- to 15-fold higher and tumor-to-blood ratios were 10- to 20-fold higher than those for 124I-Fab' at 1 and 24 h, respectively. Thyroid and stomach uptake was observed with the radioiodinated peptide several hours after injection (animals were not premedicated to reduce uptake in these tissues), but gastric uptake was much more pronounced with 124I-Fab'. Tumor visualization with 18F-FDG at approximately 1.5 h was also good but showed substantially more uptake in several normal tissues, making image interpretation in the pretargeted animals less ambiguous than with 18F-FDG. CONCLUSION Bispecific antibody pretargeting has a significant advantage for tumor imaging over directly radiolabeled antibodies and could provide additional enhancements for oncologic imaging, particularly for improving targeting specificity as compared with 18F-FDG.

[1]  M. Welch,et al.  In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  G. Denardo,et al.  New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. , 1998, Hybridoma.

[3]  D. Wilbur.  Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. , 1992, Bioconjugate chemistry.

[4]  S. Denardo,et al.  Stable bifunctional chelates of metals used in radiotherapy. , 1990, Cancer research.

[5]  Sanjiv S Gambhir,et al.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.

[6]  Chien-Hsing Chang,et al.  Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody , 2005, Nature Medicine.

[7]  E. Gautherot,et al.  Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  J. Chatal,et al.  Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Gautherot,et al.  Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. , 1997, Bioconjugate chemistry.

[10]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[11]  Gary L Griffiths,et al.  A universal pretargeting system for cancer detection and therapy using bispecific antibody. , 2003, Cancer research.

[12]  C. Meares,et al.  Antibodies against metal chelates , 1985, Nature.

[13]  T. Turkington,et al.  Clinical applications of PET in oncology. , 2004, Radiology.

[14]  M. Goris,et al.  Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. , 1999, Cancer biotherapy & radiopharmaceuticals.

[15]  J. Barbet,et al.  Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[16]  W. Mcbride,et al.  Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.

[17]  W. Mcbride,et al.  Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. , 2000, Bioconjugate chemistry.

[18]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[19]  S S Gambhir,et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Baldwin,et al.  A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines , 1991 .

[21]  M. Schwaiger,et al.  N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. , 2005, Journal of medicinal chemistry.

[22]  R. Boellaard,et al.  High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  J. Slater,et al.  Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. , 1991, Cancer research.

[24]  J. Sykes,et al.  Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α, 6α-diphenyl glycoluril (Iodogen) , 1981 .

[25]  W. McBride,et al.  Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  W. Oyen,et al.  The impact of fluor‐18‐deoxyglucose‐positron emission tomography in the management of colorectal liver metastases , 2005, Cancer.

[27]  E. Gautherot,et al.  In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  D. E. Simpson,et al.  New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  W. Mcbride,et al.  Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Sykes,et al.  Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). , 1981, Analytical biochemistry.

[31]  W. Oyen,et al.  Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection. , 2005, Cancer biotherapy & radiopharmaceuticals.

[32]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  W. Mcbride,et al.  Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft , 2005, Clinical Cancer Research.

[34]  E. Gautherot,et al.  Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. , 1990, Cancer research.

[35]  C. Meares,et al.  Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.